158 related articles for article (PubMed ID: 19449118)
21. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
[TBL] [Abstract][Full Text] [Related]
22. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
Akyol F; Ozyigit G; Selek U; Karabulut E
Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
[TBL] [Abstract][Full Text] [Related]
23. Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer.
Singh A; Zelefsky MJ; Raben A; Lombardi D; Leibel SA
Int J Cancer; 2000 Oct; 90(5):275-80. PubMed ID: 11091351
[TBL] [Abstract][Full Text] [Related]
24. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
25. [Clinical and biological evaluation of the response to neoadjuvant hormone therapy before radiotherapy in nonmetastatic cancers of the prostate].
Richaud P; Salem N; Gaston R; Mauriac L; Chacon B; Bussières E
Cancer Radiother; 1998; 2(1):27-33. PubMed ID: 9749093
[TBL] [Abstract][Full Text] [Related]
26. Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men.
Karasawa K; Kaizu T; Niibe Y; Igaki H; Shinohara M; Tanaka Y; Matsuda T
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):208-12. PubMed ID: 12694840
[TBL] [Abstract][Full Text] [Related]
27. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group.
Corn BW; Winter K; Pilepich MV
Urology; 1999 Sep; 54(3):495-502. PubMed ID: 10475361
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
29. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
30. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.
Michalski J; Winter K; Roach M; Markoe A; Sandler HM; Ryu J; Parliament M; Purdy JA; Valicenti RK; Cox JD
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e363-70. PubMed ID: 22633552
[TBL] [Abstract][Full Text] [Related]
32. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?
Valicenti RK; Winter K; Cox JD; Sandler HM; Bosch W; Vijayakumar S; Michalski J; Purdy J
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):614-20. PubMed ID: 14529764
[TBL] [Abstract][Full Text] [Related]
33. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
Noguchi M; Noda S; Yoshida M; Ueda S; Shiraishi T; Itoh K;
Int J Urol; 2004 Feb; 11(2):103-9. PubMed ID: 14706014
[TBL] [Abstract][Full Text] [Related]
34. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
[TBL] [Abstract][Full Text] [Related]
35. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
[TBL] [Abstract][Full Text] [Related]
36. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
37. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
Alexander A; Crook J; Jones S; Malone S; Bowen J; Truong P; Pai H; Ludgate C
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):23-30. PubMed ID: 19395187
[TBL] [Abstract][Full Text] [Related]
38. Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update.
Perez CA; Michalski JM; Mansur D; Lockett MA
Clin Prostate Cancer; 2002 Sep; 1(2):97-104. PubMed ID: 15046700
[TBL] [Abstract][Full Text] [Related]
39. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
Clark PE; Peereboom DM; Dreicer R; Levin HS; Clark SB; Klein EA
Urology; 2001 Feb; 57(2):281-5. PubMed ID: 11182337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]